Michael Loberg

Michael D. Loberg, PhD

Dr. Loberg has been a member of Inotek’s Board of Directors since 2005.

Dr. Loberg’s career spans more than 25 years in the pharmaceutical industry, including almost 12 years of direct involvement in drug discovery and development, notably in leadership roles in senior management and executive positions at the Bristol-Myers Squibb Company (BMS). Dr. Loberg joined NitroMed in 1997 as Chief Executive Officer. In this role, Dr. Loberg oversaw and led NitroMed’s successful initial public offering in 2003. Prior to his joining NitroMed, Dr. Loberg was President, BMS Oncology & Immunology division, where he successfully generated significant increases in sales and profitability. Previously, Dr. Loberg served as President, BMS Primary Care division; President, BMS Northern Europe; and President, BMS Specialty Pharmaceuticals.

Dr. Loberg is credited with creating the Squibb Diagnostic business unit. Before joining BMS, Dr. Loberg held an appointment as Associate Professor of Medicine in the Medicinal Chemistry and Medicine Departments at the University of Maryland Schools of Pharmacy and Medicine. Dr. Loberg is on the Board of Directors of Advanced Magnetics, Inc. and Kereos and on the Board of Advisors of the University of Minnesota College of Pharmacy.

He earned his B.S. in chemistry from Trinity College and his Ph.D. in Chemistry from Washington University in St. Louis.